Back to top
more

Vertex Pharmaceuticals (VRTX)

(Delayed Data from NSDQ)

$483.00 USD

483.00
2,259,829

-15.73 (-3.15%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Sheraz Mian headshot

Top Stock Reports for NVIDIA, UPS & Intuit

Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), United Parcel Service, Inc. (UPS), and Intuit Inc. (INTU).

Biogen (BIIB) Q4 Earnings Top, Stock Down on Weak 2022 View

Biogen (BIIB) beats fourth-quarter estimates for both earnings and sales. The stock declines on weak sales and earnings guidance for 2022.

Novo Nordisk's (NVO) Q4 Earnings and Sales Beat Estimates

Novo Nordisk's (NVO) earnings and revenues beat estimates in Q4. Sales are driven by growth in Diabetes and Obesity Care on higher GLP-1 revenues.

Gilead (GILD) Q4 Earnings Miss on Legal Settlement Charges

Gilead (GILD) misses on earnings but beats on sales in the fourth quarter. While the HIV business maintains momentum on Biktarvy, sales of Veklury decline.

Zacks.com featured highlights include: Danaos Corp., Earthstone Energy Inc., Hanmi Financial Corp., Archer-Daniels-Midland Co. and Vertex Pharmaceuticals Inc

Danaos Corp., Earthstone Energy Inc., Hanmi Financial Corp., Archer-Daniels-Midland Co. and Vertex Pharmaceuticals Inc are highlighted in this Screen of the Week article.

Zacks Industry Outlook Highlights: Regeneron, Vertex Pharmaceuticals, Dynavax Technologies Corp. and Repligen

Regeneron, Vertex Pharmaceuticals, Dynavax Technologies Corp. and Repligen are highlighted in this Industry Outlook article.

Ekta Bagri headshot

4 Top Biotech Stocks to Gain Amid Industry Challenges

New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position VRTX, REGN, DVAX and RGEN well amid the volatility.

Nalak Das headshot

5 Stocks With Recent Price Strength Amid Wall Street Turmoil

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are DAC, ESTE, HAFC, ADM and VRTX.

Panel Of Zacks Experts headshot

Top Stock Picks for Week of January 31, 2022

A Biomed Stock Well Positioned for Outperformance and a Building Materials Company Befitting From a Robust Demand Environment.

Dr. Reddy's (RDY) Q3 Earnings, Sales Increase Year Over Year

Dr. Reddy's (RDY) earnings and revenues increase year over year in third-quarter fiscal 2022.

Regeneron (REGN) Withdraws sBLA for Libtayo in Cervical Cancer

Regeneron (REGN) and partner Sanofi voluntarily withdraw the supplemental biologics license application for Libtayo in second-line treatment of advanced cervical cancer.

Looking for a Growth Stock? 3 Reasons Why Vertex (VRTX) is a Solid Choice

Vertex (VRTX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Biotech Stock Roundup: VRTX Q4 Earnings, GILD, INCYs Regulatory Updates & More

Earnings updates from Vertex (VRTX) and pipeline updates are among a few key highlights from the biotech sector during the past week.

Vertex (VRTX) Q4 Earnings & Sales Beat, '22 View Upbeat

Vertex Pharmaceuticals' (VRTX) earnings and sales surpass estimates for the fourth quarter of 2021. The company provides its revenue guidance for 2022.

Vertex Pharmaceuticals (VRTX) Surpasses Q4 Earnings and Revenue Estimates

Vertex (VRTX) delivered earnings and revenue surprises of 2.74% and 4.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals Inc., Marten Transport, Nucor, Seagate Technology and Sanderson Farms

Vertex Pharmaceuticals Inc., Marten Transport, Nucor, Seagate Technology and Sanderson Farms are included in this blog.

Sejuti Banerjea headshot

5 Buy-Ranked Stocks Likely to Beat on Earnings This Week

The Zacks Rank and ESP are still a solid combination to predict earnings beats.

The Zacks Analyst Blog Highlights: Tesla Inc., Steel Dynamics Inc., United Rentals Inc., Freeport-McMoRan Inc. and Vertex Pharmaceuticals Inc.

Tesla Inc., Steel Dynamics Inc., United Rentals Inc., Freeport-McMoRan Inc. and Vertex Pharmaceuticals Inc. are included in this blog.

Should You Buy Vertex Pharmaceuticals (VRTX) Ahead of Earnings?

Vertex Pharmaceuticals (VRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?

Investors are likely to focus on Vertex Pharmaceuticals' (VRTX) CF product revenues, especially sales of its triple combo CF drug Trikafta/Kaftrio, and non-CF pipeline progress.

AbbVie's (ABBV) Skyrizi Gets FDA Nod for Psoriatic Arthritis

AbbVie (ABBV) secures approval in the United States for Skyrizi to treat adult patients with active psoriatic arthritis.

Will Lower Aggregate Revenues Hurt Intel's (INTC) Q4 Earnings?

Intel's (INTC) performance in fourth-quarter 2021 is likely to reflect headwinds in the enterprise business of the data center segment.

Silicon Motion (SIMO) to Report Q4 Earnings: What's in Store?

Silicon Motion's (SIMO) performance in the fourth quarter of 2021 is likely to have benefited from increased sales of SSD and eMMC and UFS controllers.

PTC Gearing Up for Q1 Earnings: What is in the Offing?

PTC is likely to have reported higher year-over-year revenues in first-quarter fiscal 2022, driven by significant growth across all product segments and regions.

Vertex Pharmaceuticals (VRTX) Stock Moves -0.23%: What You Should Know

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $228.08, marking a -0.23% move from the previous day.